Pharmaceutical

5 takeaways from Trump's drug pricing speech

5 takeaways from Trump's drug pricing speech

By

Pharma stocks were up after the President went easy on drugmakers.

Jay Appel, Bristol-Myers Squibb

Jay Appel, Bristol-Myers Squibb

Jay Appel is executive director of Bristol-Myers Squibb.

Heather Bell, Sanofi

Heather Bell, Sanofi

Heather Bell is SVP, global head of digital and analytics of Sanofi.

Ryan Billings, Amag Pharmaceuticals

Ryan Billings, Amag Pharmaceuticals

Ryan Billings is the senior director, digital innovation at Amag Pharmaceuticals.

Ozgun Demir, Novartis

Ozgun Demir, Novartis

Ozgun Demir is the director, digital strategy at Novartis.

Dr. Jessica Grossman, Medicines360

Dr. Jessica Grossman, Medicines360

Dr. Jessica Grossman is CEO of Medicines360.

Grant Groves, Boehringer Ingelheim

Grant Groves, Boehringer Ingelheim

Grant Groves is global customer innovation lab, U.S. lead at Boehringer Ingelheim.

Kishore Kumar, AstraZeneca

Kishore Kumar, AstraZeneca

Kishore Kumar is head of oncology innovation and integration at AstraZeneca.

Laurie Myers, Merck

Laurie Myers, Merck

Laurie Myers is global health literacy director of Merck.

Doug Noland, Astellas

Doug Noland, Astellas

Doug Noland is head, patient experience at Astellas.

Sandra Shpilberg, Seeker Health

Sandra Shpilberg, Seeker Health

Sandra Shpilberg is founder and CEO of Seeker Health.

Justin Chase, Intouch Solutions

Justin Chase, Intouch Solutions

Justin Chase is EVP and head, innovation and media at Intouch Solutions.

Susan Dorfman, CMI/Compas

Susan Dorfman, CMI/Compas

Susan Dorfman is chief commercial officer of CMI/Compas.

Dan Renick, Precision Value & Health

Dan Renick, Precision Value & Health

Dan Renick is president of Precision Value & Health.

McCaskill takes aim at DTC ad tax deduction; measure expected to face stiff resistance

McCaskill takes aim at DTC ad tax deduction; measure expected to face stiff resistance

Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.

Teva rebrands in North America amid global restructuring

Teva rebrands in North America amid global restructuring

By

The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.

PhRMA takes Let's Talk About Cost campaign to the public

PhRMA takes Let's Talk About Cost campaign to the public

By

PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.

Flexion's pivot proves pain-free

Flexion's pivot proves pain-free

By

Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.

Front seat to the comms evolution: Abbott's Melissa Brotz

Front seat to the comms evolution: Abbott's Melissa Brotz

By

The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.

Otsuka's April Mitchell on leading versus managing

Otsuka's April Mitchell on leading versus managing

By

When you've figured out the difference, people will walk through fire for you, a mentor once told her.

Twitter, Facebook, Google execs examine regulatory limits for drugmakers

Twitter, Facebook, Google execs examine regulatory limits for drugmakers

By

Technology executives discussed how pharma companies can leverage social media to better engage with patients online.

Five things for pharma marketers to know: Monday, September 28, 2015

Five things for pharma marketers to know: Monday, September 28, 2015

By

PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk's shares rise on Tresiba approval

New Turing CCO steps down amid drug price controversy

New Turing CCO steps down amid drug price controversy

By

Craig Rothenberg joined Turing as its first comms chief less than two months ago.

Purdue debuts opioid-abuse resource

Purdue debuts opioid-abuse resource

By

Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.

Allergan sales rise on "strong" DTC advertising

Allergan sales rise on "strong" DTC advertising

By

Allergan executives attributed strong sales of branded products to recent investments in direct-to-consumer advertising.

Five things for pharma marketers to know: Thursday, August 6

Five things for pharma marketers to know: Thursday, August 6

By

AstraZeneca signs two immuno-oncology collaboration deals; UK cost watchdog goes after Pfizer over epilepsy medication price tag; Boston Globe reports drugmakers are funneling more money through CME programs

Eylea erodes Lucentis, Avastin market share

Eylea erodes Lucentis, Avastin market share

By

Eylea's robust second quarter of sales can be attributed in part to its ability to erase market share of competitors.

Express Scripts drops Onglyza from 2016 formulary over safety concerns

Express Scripts drops Onglyza from 2016 formulary over safety concerns

By

The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.

Five things for pharma marketers to know: Monday, August 3

Five things for pharma marketers to know: Monday, August 3

By

Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010

The MM&M Weekly News Quiz: July 31

The MM&M Weekly News Quiz: July 31

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.